Stay updated with breaking news from Phasei Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
DOYLESTOWN, Pa., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical stage biopharmaceutical company focused on precision oncology through synthetic
Drs Gutierrez and Leslie discuss common barriers that institutions face when implementing CAR T-cell therapy programs, the early success story of outpatient administration of this modality at John Theurer Cancer Center, and future considerations for using this treatment approach in solid tumors.
/PRNewswire/ -- USA News Group - Since September 2022, the US Food and Drug Administration (FDA) has seen new treatments for pancreatic cancer that are worthy...
USA News Group – Since September 2022, the US Food and Drug Administration (FDA) has seen new treatments for pancreatic cancer that are worthy of further investigation or approval. Known as one of the deadliest cancers on earth, analysis published ...
Kathleen N. Moore, MD, MS, discusses the design of the ongoing, first-in-human, phase 1/2 study of the MUC16- and CD3-targeted bispecific antibody ubamatamab alone or in combination with cemiplimab in patients with recurrent ovarian cancer.